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Abstract
It is unclear how systemic administration of mesenchymal stem cells (MSCs) controls local
inflammation. The aim of this study was to evaluate the therapeutic effects of human MSCs
on inflammatory arthritis and to identify the underlying mechanisms. Mice with collagen anti-
body-induced arthritis (CAIA) received two intraperitoneal injections of human bone mar-
row-derived MSCs. The clinical and histological features of injected CAIA were then
compared with those of non-injected mice. The effect of MSCs on induction of regulatory T
cells was examined both in vitro and in vivo. We also examined multiple cytokines secreted
by peritoneal mononuclear cells, along with migration of MSCs in the presence of stromal
cell-derived factor-1 alpha (SDF-1α) and/or regulated on activation, normal T cell expressed
and secreted (RANTES). Sections of CAIA mouse joints and spleen were stained for human
anti-nuclear antibodies (ANAs) to confirm migration of injected human MSCs. The results
showed that MSCs alleviated the clinical and histological signs of synovitis in CAIA mice.
Peritoneal lavage cells from mice treated with MSCs expressed higher levels of SDF-1α and
RANTES than those from mice not treated with MSCs. MSC migration was more prevalent
in the presence of SDF-1α and/or RANTES. MSCs induced CD4+ T cells to differentiate into
regulatory T cells in vitro, and expression of FOXP3 mRNA was upregulated in the forepaws
of MSC-treated CAIA mice. Synovial and splenic tissues from CAIA mice receiving human
MSCs were positive for human ANA, suggesting recruitment of MSCs. Taken together,
these results suggest that MSCs migrate into inflamed tissues and directly induce the differ-
entiation of CD4+ T cells into regulatory T cells, which then suppress inflammation. Thus,
systemic administration of MSCs may be a therapeutic option for rheumatoid arthritis.
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Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects joints and bones. The
pathologic hallmarks of RA are synovial inflammation and subsequent destruction of cartilage
and bone [1]. In general, the pathogenesis of RA is characterized by overactivation of pro-
inflammatory immune responses, resulting in pannus formation and inflamed synovial tissues
[2]. However, recent studies suggest that the regulatory function of the immune system in RA
patients is impaired. The number of circulating regulatory T (Treg) cells within the peripheral
blood mononuclear cell population in RA patients is lower than that in healthy controls and
patients with osteoarthritis [3, 4]; also the suppressive capacity of Treg cells in patients with
active RA is compromised [5]. The finding that anti-rheumatic drugs such as methotrexate
and biologic agents induce a significant rise in both the number and activity of Treg cells [5, 6]
also suggests that immune regulatory function plays an important role in the pathogenesis of
RA.
Recent advances in RA treatment based on pathophysiological insights have led to a signifi-
cant improvement in the clinical outcome for patients. However, many patients still fail to
reach the therapeutic target under current treatments. Moreover, RA patients often experience
adverse events because the therapeutic modalities suppress normal host immune responses.
Therefore, there is a need to explore alternative immune modulatory therapies that will restore
the balance between the inflammatory and regulatory functions of the immune system. One
such strategy is cell-based therapy.
Mesenchymal stem cells (MSCs) are a promising candidate for immune modulatory cell-
based therapy. MSCs are adult stromal cells that show increased proliferation and multipo-
tency (i.e., they can differentiate into various cell types). Although MSCs were originally iden-
tified as plastic-adherent cells that support hematopoiesis [7], current evidence suggests that
they may play a therapeutic role in inflammatory conditions. Intravenous or intraperitoneal
injection of MSCs into experimental animal models of inflammatory disease reduces both clin-
ical severity and histologic grade [8]. Moreover, the capacity to proliferate and differentiate
makes MSCs an attractive source for cell-based therapy.
The immune regulatory properties of MSCs are thought to be mediated via cell-to-cell
interactions. Previous studies suggest that MSCs must make contact with immune cells to
induce immune regulatory functions and inhibit pro-inflammatory functions [9–13]. Migra-
tion and appropriate recruitment of the injected MSCs are critical for a successful outcome;
indeed, several preclinical models report successful treatment of inflammatory disease after
local injection of MSCs at inflammatory sites [14, 15]. However, systemic administration of
MSCs also alleviates local inflammation, suggesting that injected MSCs migrate to the sites
where they are needed [16–20]. Also, the wide range of bioactive molecules (which have
immunomodulatory, anti-apoptotic, anti-inflammatory, chemotactic, and regenerative prop-
erties) secreted by MSCs have therapeutic efficacy in inflamed lesions [21]. Several studies
show that the therapeutic effects of migrated MSCs in various animal models of disease may
be due to secretion of chemokines/cytokines. While some notable studies have examined the
effects of MSCs in arthritis, none has examined mouse models of collagen antibody-induced
arthritis (CAIA).
Here, we examined the therapeutic effects of MSCs in mice with inflammatory arthritis to
identify the mechanisms underlying their immune regulatory properties. We compared the
clinical and histological severity of CAIA in mice injected with or without MSCs and evaluated
local chemokine production and cell migration in vivo.
Immune regulation by mesenchymal stem cells in collagen antibody induced arthritis mice
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Materials and methods
Mice
Six-week-old female DBA1/J mice were purchased from OrientBio (Seongnam, Korea) and
maintained under pathogen-free conditions. Arthritis was induced when mice were 7 weeks
old. All procedures were undertaken in accordance with the Laboratory Animals Welfare
Act and the Guide for the Care and Use of Laboratory Animals, and with the Guidelines
and Policies for Rodent Experimentation provided by the Institutional Animal Care and
Use Committee of the Catholic University of Korea. The study was approved by the Animal
Research Ethics Committee of the Catholic University of Korea (CUMC-2015-0150-01).
Animals were housed in groups of five and maintained in an environment-controlled room
at 22˚C under a 12:12 hour light:dark cycle. To minimize animal suffering, all mice were
fully anesthetized under gas anesthesia using isoflurane (2–2.5%) and sacrificed by cervical
dislocation.
Induction of CAIA
Mice were injected intraperitoneally with a cocktail of monoclonal antibodies specific for epi-
topes on type II collagen (2 mg; Chondrex, WA, USA). After 3 days, mice received 50 μg of
lipopolysaccharide (LPS; Chondrex, WA, USA) as previously described [22]. Development of
arthritis was monitored every day for 14 days post-injection of the monoclonal antibody cock-
tail. The severity of arthritis was scored on scale of 0 to 4 in a blinded manner as follows:
0 = normal; 1 = mild swelling confined to the ankle joint or tarsal joints; 2 = mild swelling
extending to the mid-foot; 3 = moderate swelling extending to the metatarsal joints; or
4 = severe swelling encompassing the ankle, foot and digits. The scores for all four paws were
summed to generate the final arthritis score.
Preparation and delivery of MSCs
MSCs derived from human bone marrow were purchased from the Catholic Institute of Cell
Therapy, South Korea and maintained in Dulbecco’s Modified Eagle’s Medium (DMEM;
Gibco, Grand Island, NY, USA) containing 20% fetal bovine serum (FBS; Gibco, Grand Island,
NY, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin (Gibco, Grand Island, NY,
USA). On the day following injection of LPS, CAIA mice received an intraperitoneal injection
of 5 × 106 MSCs in 500 μL of phosphate-buffered saline (PBS), followed by a second injection
of 5 × 106 MSCs 3 days later.
Histopathological analysis
On Day 14 post-injection of anti-type II collagen antibodies, CAIA mice were euthanized
and the hind paws fixed in 10% formaldehyde for 2 days. Paws were then decalcified in 10%
ethylenediamine tetraacetic acid (EDTA) for 30 days at 4˚C and embedded in paraffin. The
joint tissues were then cut into 4 μm sections and stained with haematoxylin and eosin
(H&E), toluidine blue, and safranin O. The severity of histopathological arthritis was deter-
mined on a scale from 0 to 3 as previously described [23]: 0 = no arthritis; 1 = mild arthritis;
2 = moderate arthritis; and 3 = severe arthritis. Synovial inflammation and articular
destruction were evaluated according to the extent of cellular infiltration and pannus for-
mation, and loss of cartilage and bone, respectively. Histological scoring was performed by
three independent investigators.
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Real-time polymerase chain reaction
Mouse forepaws were homogenized using a gentle MACS Dissociator (Miltenyi Biotec, Ber-
gisch Gladbach, Germany), and samples were incubated with Trizol (Invitrogen, Life Technol-
ogies, Carlsbad, CA, USA) to extract mRNA. cDNA was synthesized from 2 μg of extracted
total RNA using the RevertAidTM First Strand cDNA Synthesis kit (Thermo Fisher Scientific).
Real-time PCR was carried out using a LightCycler1 480 Instrument II (Roche, Basel, Swit-
zerland). Expression of mouse Foxp3 was determined using the following primers: Forward,
CAAGGTGAGCGAGTGTCCCTGCTC; and Reverse, AGTTGCCGGGAGCTGGAGTGG.
Mean cycle threshold values from triplicate experiments were used to calculate gene expres-
sion, which was normalized to gapdh (internal control).
Isolation of peritoneal cells
The outer layer skin on the abdominal wall was removed to expose the peritoneum covered by
the inner layer of skin. Sterile PBS (5 mL) was then injected into the peritoneal cavity using a 5
mL syringe fitted with a 27-gauge needle. After gently rubbing the peritoneum, the peritoneal
fluid was collected in the same syringe. The fluid was centrifuged at 1500 × g for 6 min and the
supernatant removed. Cytokine and chemokine expression by the isolated cells was then ana-
lyzed (see below).
Mouse cytokine/Chemokine array
A mouse cytokine array was used for simultaneous detection of 62 cytokines according to the
manufacturer’s protocol (ab133995, Abcam, Cambridge, MA, USA). Briefly, mouse peritoneal
cells were lysed in cell lysis buffer comprising 0.1 M Tris (pH 7.6) containing 0.15 M NaCl and
0.5% Nonidet P-40. The cell lysate was then added to the membrane of a mouse cytokine
array. After washing the membrane, the detection antibody was applied and immunoblot
images were captured using the BioSpectrum Imaging System. The intensity of each spot was
measured using Image J software (version 1.44, NIH, Maryland, USA).
T cell differentiation and co-culture with MSCs
CD4+ T cells were isolated from CAIA mouse splenocytes using a magnetic sorter and
microbeads coated with an anti-CD4 antibody (Miltenyi Biotec, Bergisch Gladbach, Ger-
many). CD4+ T cells were then stimulated with 1 μg/mL plate-bound anti-CD3 (BD Biosci-
ences, San Jose, CA, USA) and 2 μg/mL anti-mouse CD28 (BD Biosciences, San Jose, CA,
USA) in RPMI-1640 supplemented with 10% FBS. After 2 h, T cells were differentiated into
Treg or type 17 T helper (Th17) cells under specific conditions. Briefly, Treg cells were induced
for 3 days in the presence of anti-mouse interleukin (IL)-4 (2 μg/mL), anti-mouse interferon-γ
(IFN-γ, 2 μg/mL), and transforming growth factor-β (TGF-β, 1 ng/mL). For Th17 differentia-
tion, CD4+ T cells were treated for 3 days with recombinant IL-6 (20 ng/mL), anti-mouse IL-4
(2 μg/mL), anti-mouse IFN-γ (2 μg/mL), and TGF-β (2 ng/mL). All growth factors were pur-
chased from R&D systems (Minneapolis, MN, USA). To evaluate the in vitro effect of MSCs,
5 × 104 MSCs were added to T cell culture on Day 1 of the Treg and Th17 differentiation.
Flow cytometry
Treg/Th17 cells were cultured in the presence or absence of MSCs and then stained with rat
anti-mouse CD4 antibodies conjugated to APC (BD Biosciences, San Jose, CA, USA), and
with anti-mouse CD25 antibodies conjugated to APC-Cy7 (BD Biosciences, San Jose, CA,
USA). After permeabilizing T cells using a buffer set (eBioscience, Waltham, MA, USA), Treg
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and Th17 cells were stained with anti-Foxp3 antibodies conjugated to FITC (eBioscience, Wal-
tham, MA, USA), and with anti-human/mouse RORγt antibodies conjugated to PE
(eBioscience, Waltham, MA, USA), respectively. Cells were then examined in an LSR Fortessa
cell analyzer (BD Biosciences). Data were analyzed using FlowJo 7.6.5 software (TreeStar Inc.,
Ashland, OR, USA).
In vitro scratch assay
Human MSCs were cultured to 90% confluence in 6-well plates (Corning-Coaster, Tokyo,
Japan). The cell monolayer was then scratched with a 200 μL pipette tip to generate a vertical
line. MSCs were cultured with PBS/DMEM containing 10% FBS in the presence of 500 ng/mL
CXCL12/stromal cell-derived factor-1 alpha (SDF-1α; R&D systems, Minneapolis, MN, USA)
and 500 ng/mL CCL5/regulated on activation, normal T cell expressed and secreted (RANTES;
R&D systems). MSCs migrating into the wounded area were photographed and counted both
before and after treatment with SDF-1α and RANTES. Images were acquired every 2 h
between 0 and 12 h. The number of migrating cells was counted by three independent
observers.
Transwell migration assay
Chemotaxis of MSCs was evaluated using commercially available Transwell1 polycarbonate
membrane cell culture inserts in 24-well plates (CLS3422, Sigma-Aldrich, St. Louis, MO, USA)
[24]. The assay system comprised two chambers that were separated by a polycarbonate mem-
brane (6.5 mm in diameter). The membrane is cell permeable, with evenly distributed 8.0 μm
pores.
Serum-starved MSCs (1 × 104 cells/250 μL DMEM) were loaded into the upper chamber.
The lower chamber was filled with 450 μL of serum-free DMEM containing 0.1% bovine
serum albumin (Sigma-Aldrich, St. Louis, MO, USA), 500 ng/mL SDF-1α, or 500 ng/mL
RANTES. After 7 h, cells remaining in the upper chamber were removed. Cells migrating to
the lower chambers were stained with crystal violet solution and counted by three independent
investigators.
Statistical analysis
Experimental data are expressed as the mean and standard error of the mean (SEM). Statistical
significance was determined using Student’s t-test. A p-value<0.05 was considered significant.
All data were analyzed using SAS software (v. 9.1; SAS Institute, Cary, NC, USA) and Graph-
Pad Prism software (v. 5.01; GraphPad, San Diego, CA, USA).
Results
MSCs alleviate inflammatory arthritis
Mice injected with collagen antibody cocktail developed inflammatory arthritis after LPS
administration. CAIA mice received two doses of human MSCs, with a 3-day interval between
doses (Fig 1A). Human MSCs significantly attenuated inflammatory arthritis in CAIA mice
(Fig 1B). The arthritis score of CAIA mice treated with MSCs did not change significantly
after injection with MSCs; however, the score of control CAIA mice increased steadily until it
reached a plateau at 6 days post-injection of the collagen antibody cocktail (Fig 1C). The artic-
ular structures in MSC-treated CAIA mice were better preserved than those in control CAIA
mice (Fig 1D). H&E staining of sections from control CAIA mice revealed prominent infiltra-
tion of synovial tissues by inflammatory cells. The results of safranin O staining and toluidine
Immune regulation by mesenchymal stem cells in collagen antibody induced arthritis mice
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blue staining showed slightly higher levels of cartilage erosion in control CAIA mice than in
MSC-injected CAIA mice. Both the inflammation score and the destruction score were signifi-
cantly lower in CAIA mice treated with MSCs than in control CAIA mice.
MSCs migrate to inflamed lesions in CAIA mice
To confirm whether the curative effects were caused by migrated MSCs, we checked for the
presence of human cells by staining sections of hindpaws with human anti-nuclear antibodies
(ANA). Positive staining for ANA in CAIA mice hindpaws injected with MSCs showed GFP
expression, indicating human cells (Fig 2A). No human ANA-positive cells were observed in
control CAIA mice. To examine the effects of MSCs in vivo, we measured relative expression
of FOXP3 and IL-17 mRNA in forepaw homogenates from CAIA mice and MSC-treated
CAIA mice. Expression of mouse FOXP3 (mFOXP3) in the forepaw of CAIA mice injected
with MSCs increased. Expression was significantly higher (almost eight times) than that in
control CAIA mice and wild-type DBA/1J mice (p< 0.001) (Fig 2B). Expression of IL-17 also
increased (Fig 2C); however, the change was not as high as that for FOXP3. There were no sig-
nificant differences between CAIA mice treated with and without MSCs in terms of expression
of mFOXP3 or mIL-17 in the spleen (S1 Fig). Previous studies show that MSCs migrate toward
inflammatory sites; the data presented herein confirm that MSCs also migrate to inflamed
areas in the CAIA mouse model.
Migrated MSCs promote Treg differentiation in situ
Several reports show that a large proportion of injected MSCs migrate to the spleen [25–28],
an organ involved in T cell development and activation. Staining sections of spleen from
CAIA mice with human ANAs confirmed the presence of human MSCs among cellular aggre-
gates (Fig 3A). Splenic tissues from CAIA mice treated with human MSCs contained posi-
tively-stained cells, indicating migration of injected MSCs. However, no human ANA-positive
cells were observed in wild-type mice or control CAIA mice. Spleen sections were also stained
with antibodies specific for mouse FOXP3 to assess the loco-regional response by migrated
MSCs. Expression of FOXP3 was significantly higher in CAIA mice treated with MSCs than in
control CAIA mice. Of note, FOXP3+ cells were predominantly found in close proximity to
human MSCs.
CD4+ splenocytes obtained from CAIA mice were cultured with or without MSCs (5 × 104)
under conditions that stimulate differentiation into Treg cells or Th17 cells. There was a signif-
icant increase in the percentage of CD4+FOXP3+ T cells in the presence of MSCs (4.84% vs.
10.3%, respectively; p< 0.05) (Fig 3B). MSCs also reduced Th17 differentiation (7.0%
(absence) vs. 0.63% (presence); p< 0.001) (Fig 3C).
Overexpression of SDF-1α and RANTES induces migration of MSCs
Previous studies suggest that MSCs exert immune regulatory effects by inducing chemokine
production. To evaluate regional responses by MSCs, we compared expression of various
Fig 1. Treatment with MSCs alleviates inflammatory arthritis in mice. (A) Time schedule for induction of CAIA and treatment with MSCs.
CAIA mice received two intraperitoneal injections of MSCs (5 × 106 cells each), with a 3-day interval in between. (B) Clinical photographs of the
hind paws of wild-type DBA/1J (WT) mice, control CAIA mice (CAIA), and CAIA mice treated with MSCs (CAIA+MSC) at Day 14. (C) Clinical
severity of CAIA in each group after injection of a collagen antibody cocktail. Arthritis severity in each paw was scored from 0 (no swelling) to 4
(erythema and severe swelling of entire tarsal joint) and expressed as the mean of the sum of three paws (0–12) ± the standard error of the mean
(SEM). (D) Histologic analysis of hind paws from each group at Day 14. Tarsal joints were stained with haematoxylin and eosin (H&E), safranin
O, and toluidine blue. Synovial inflammation and bone erosion were evaluated on a scale from 0 to 3. The histological score was expressed as the
mean of the scores determined by three independent examiners (± SEM).  p< 0.001.
https://doi.org/10.1371/journal.pone.0198740.g001
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chemokines in the peritoneal cavity of CAIA mice treated with or without MSCs. Lysates of
mononuclear cells isolated from intraperitoneal wash fluid were analyzed using a membrane
antibody array (S2 Fig). Among 62 cytokines, signals generated by RANTES and SDF-1α were
higher in CAIA mice treated with MSCs than in mice not treated with MSCs (Fig 4A). Because
RANTES and SDF-1α promote chemotaxis [29–35], we next examined migration of MSCs in
the presence or absence of RANTES and SDF-1α. Migration of MSCs was measured in vitro
using a scratch assay and a Transwell migration assay. Both assays showed that MSC migration
increased in the presence of RANTES or SDF-1α (Fig 4B and 4C). No additive effect was
noted. These results suggest that RANTES and SDF-1α may play a role in the curative effects
of MSCs in CAIA mice.
Discussion
The present study shows that treatment of CAIA mice with MSCs alleviates inflammatory
arthritis through MSC-mediated induction of Treg cells. Chemokine expression in the perito-
neal cavity of CAIA mice treated with MSCs suggests that increased expression of SDF-1α and
RANTES promotes migration of MSCs into inflamed joints, where they may induce differenti-
ation of CD4+ T cells into Treg cells.
Fig 2. MSCs migrated to inflamed paws and regulated mouse FOXP3 and IL-17 mRNA expression (A) The joints of CAIA mice were stained
with human anti-nuclear antibodies (ANAs) to confirm the presence of human MSCs. Expression of (B) mouse FOXP3 mRNA and (C) IL-17 in
forepaws of mice from each group. To evaluate in vivo expression of mFOXP3 and mIL-17, mRNA was extracted from the homogenized forepaws
of CAIA mice from each group. Data are expressed as the mean ± SEM.  p< 0.01;  p< 0.001.
https://doi.org/10.1371/journal.pone.0198740.g002
Immune regulation by mesenchymal stem cells in collagen antibody induced arthritis mice
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Fig 3. MSCs migrate to the spleen of CAIA mice. (A) Splenic tissues were stained with antibodies specific for mouse FOXP3 to detect
FOXP3+ Treg cells. Images of FOXP3+ cells and human ANA+ cells were merged to evaluate the spatial relationship between MSCs and Treg
cells. The original magnification is shown in the right panel of each figure. Flow cytometry analysis of CD4+ T cells isolated from splenocytes
of control CAIA mice cultured under (B) Treg and (C) Th17 differentiation conditions. Representative images and percentages of each cell
types are shown are shown in the graph on the right.
https://doi.org/10.1371/journal.pone.0198740.g003
Immune regulation by mesenchymal stem cells in collagen antibody induced arthritis mice
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Fig 4. SDF-1α and RANTES induced by MSC treatment promote migration of MSCs. (A) Expression of multiple chemokines in peritoneal
mononuclear cells of CAIA mice treated with or without MSCs. Mononuclear cells were isolated from peritoneal wash fluid from CAIA mice. (B) In
vitro scratch assay to examine MSC migration in the absence or presence of SDF-1α and RANTES. The number of MSCs migrating into the gap was
counted every 2 h (between 0 and 12 h) by three independent examiners. Representative images taken at 0 and 12 h are shown. (C) Transwell
Immune regulation by mesenchymal stem cells in collagen antibody induced arthritis mice
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The immunomodulatory properties of MSCs have been demonstrated in several animal
models of inflammatory disease, including collagen-induced arthritis (CIA), experimental
autoimmune encephalomyelitis (EAE), and experimental colitis [36]. In line with previous
studies, we found that treating arthritic mice with human MSCs improved the clinical and his-
tological grade of arthritis. The CIA mouse model is generated by intradermal injection of
type II collagen (emulsified in Complete Freund’s Adjuvant) to induce a pathology that shares
many similarities with RA. CIA requires active participation of T and B cells to generate com-
plement fixing antibodies that bind to murine cartilage and initiate a destructive pathology.
Toupet and colleagues confirmed migration of intravenously (IV)- or intra-articularly (IA)-
injected adipose-derived MSCs in inflamed lesions of CIA mice [37]. T helper 1 cells isolated
from spleen or lymph nodes of CIA mice injected IV with adipose stem cells (ASCs) showed
decreased populations of CD4+IFN-γ+ cells and CD4+IL17+ cells, but a significant increase in
CD4+IL10+ cells. The arthritis score of CIA mice injected with ASCs was also lower than that
of CIA mice. In addition, 100% of ASCs injected into wild-type mice and CIA mice were
detected in the lung. However, the number of these cells in the lung had fallen by Day 10 post-
injection. The authors also confirmed the therapeutic effects in collagenase induced osteoar-
thritis models. When delivered via IA injection, cells were detected in the muscle and knee
joints of mice. More than 90% of injected cells were detected in the knee joint on Day 1; how-
ever, cell numbers had fallen by ~30% on Day 10.
Another study by Toupet and colleagues confirmed the effect of IA-injected ASCs in severe
combined immunodeficient (SCID) mice [26]. During the early stage post-injection, cells were
distributed throughout various organs, including the brain, heart, and blood. However, on
Day 186, cells had disappeared from most organs; cells remained only in muscle, fat tissue, and
the knee joint. When delivered via IV injection, cells were detected in lung, brain, heart, liver,
and joints; however, the number of cells in the knee joint fell by Day 28.
Another study confirmed the effects of MSCs in EAE mice [38]. MSCs were isolated from
mouse bone marrow and characterized. In addition, isolated mouse MSCs were co-cultured
with T cells and the differentiated cell subtypes analyzed. An MSC-Th1 ratio of 1:10 in co-cul-
tures successfully suppressed differentiation into CD4+IFN-γ+ cells and CD4+IL17A+ cells.
Co-culture at a ratio of 1:100 ratio did not lead to a significant increase in inhibition of Th1 dif-
ferentiation. However, co-culture of MSCs generated CD4+CD25+ cells, and this population
tended to increase from Day 0 to Day 4. The increased population of CD4+CD25+ Treg cells
was associated with increased levels of IL-10 in the supernatant of co-cultured cells. The
reduced population of activated Th17 cells was also caused by increased IL-10 levels.
Previously, we confirmed the therapeutic effects of bone marrow-derived MSCs in interleu-
kin-1 receptor antagonist knock out (IL-1RaKO) osteoarthritis mice [39]. The reduced arthri-
tis score in IL-1RaKO mice was mirrored by a decrease in the thickness of the swollen paw.
Intraperitoneally-injected MSCs reduced the CD4+RORγt+ population and increased the
CD4+CD25+FOXP3+ population. Expression of several cytokines was also detected in the
joints; human IL-1Ra was detected only in mice injected with human MSCs. Expression of
mouse IL-1β in MSC-injected IL-1RaKO mice fell, as did that of IL-6, TNF-α and IL-17.
Mouse spleen stained positive with an anti-human mitochondria antibody, confirming migra-
tion of human MSCs. Mice injected with MSCs expressed human mitochondria; however, the
migration assay to examine MSC migration in response to SDF-1α and RANTES. The two chambers were separated by a cell permeable
polycarbonate membrane. The upper chamber was loaded with MSCs and the lower chamber was filled with DMEM containing bovine serum
albumin (control), SDF-1α, or RANTES. After 7 h, the number of MSCs migrating into the lower chamber was counted by three independent
observers. Data are expressed as the mean ± standard error of the mean (SEM).  p< 0.01;  p< 0.001.
https://doi.org/10.1371/journal.pone.0198740.g004
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population of cells expressing mouse CD4 fell significantly in regions containing MSCs. When
splenocytes from these mice were isolated and Th17 differentiation induced, splenocytes from
mice injected with MSCs generated a lower percentage of Th17 cells. Co-culture of MSCs with
mouse T cells led to a reduction in Th17 cells, which was caused by human IL-1Ra secreted by
human MSCs. Supplementation with human IL-1Ra protein had the same effect on the Th17
population.
Here, we used a mouse model of CAIA. Generation of CAIA bypasses all upstream primary
immune responses by triggering anti-type II collagen antibody/complement fixing activity.
The downstream (complement cascade/other inflammatory mediators) pathways activated in
CAIA models means that the mechanism(s) underlying disease are markedly different from
those in different RA animal models; therefore, CAIA mice are a good model for learning
more about the mechanisms underlying inflammatory arthritis after LPS stimulation [22]. The
major advantage of using CAIA mice for these experiments lies in the fact that there is a short
interval between administration of MSCs and development of arthritis. Because histopatholog-
ical analysis was performed within 7 days of the second MSC injection, we were able to exam-
ine their localization in murine tissues by staining sections with human ANAs. Human ANA-
positive cells were clearly identified in the inflamed joints and spleen of CAIA mice treated
with MSCs, whereas no such cells were detected in CAIA mice not treated with MSCs. In addi-
tion, despite the short experimental time, we confirmed that injection of MSCs can alter the T
cell population in the spleen and inflamed paw.
We also showed that MSCs exert anti-inflammatory effects by inducing Treg cells. Cultur-
ing T cells with MSCs in vitro induced Treg cells and suppressed Th17 cells, thereby skewing
the Treg/Th17 balance toward Treg cells. Similarly, interaction between MSCs and T cells in
the inflamed tissue induced Treg differentiation. Expression of FOXP3 in synovial tissues of
MSC-treated CAIA mice was significantly higher than that in untreated CAIA mice, indicating
that MSCs induce Treg cells.
Interestingly, MSCs localized to splenic tissue were surrounded by FOXP3+ Treg cells, sug-
gesting that spatial proximity is crucial for MSC-induced T cell differentiation into Treg cells.
Previous studies indicate that interaction between MSCs and T cells requires direct cell-to-cell
contact, and that paracrine factors have no significant effect [9–12]. Thus, accumulated Treg
cells would be expected to originate from the systemic circulation or to be induced in situ. The
present study suggests that migratory MSCs contribute to induction of Treg cells at inflamma-
tory sites. Although MSCs are thought to have homing properties, few reports show convinc-
ing evidence of migration to injured or inflamed sites [40–43]. Most of these studies
confirmed the presence of MSCs in local tissues by identifying foreign DNA or chromosomes.
Systemically administered MSCs migrate to inflammatory sites and influence T cell differenti-
ation and chemokine production, leading to suppression of local inflammatory responses.
The mechanisms underlying MSC migration involve increased production of chemokines
that drive chemotaxis of inflammatory or immune cells. Peritoneal mononuclear cells from
CAIA mice treated with MSCs showed upregulated expression of SDF-1α and RANTES. SDF-
1α, a ligand of CXC chemokine receptor 4 (CXCR4), is a well-known chemoattractant that
induces MSC migration in a dose-dependent manner [29–32]. MSCs express CXCR4 and
interact with SDF-1α to increase their homing capacity. Here, we showed that RANTES also
promotes MSC chemotaxis. RANTES was originally identified as a paracrine factor involved
in chemotaxis of mononuclear cells [33–35]. A single study suggested increased migration of
MSCs into the joints of osteoarthritic mice in the presence of RANTES [44]. Thus, we hypoth-
esized that the altered microenvironment induced by MSCs further affects chemotaxis of
MSCs, and confirmed that SDF-1α and RANTES promote MSCs migration in vitro.
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Migration induced by RANTES and SDF-1α is reported by several studies. Ponte and col-
leagues examined the effect of several growth factors and chemokines on MSC migration [45].
Of nine chemokines selected from the CC, CXC, and CX3C families, only RANTES, MDC,
and SDF-1 showed significant chemotactic activity. In addition, when MSCs were treated with
TNF-α, they showed increased migration toward RANTES, SDF-1α, and MDC. Further exam-
ination confirmed the chemotactic activity of RANTES and SDF-1α by evaluating binding to
MSCs. Both RANTES and SDF-1α bound to unstimulated MSCs; however, only RANTES
showed increased binding after stimulation with TNF-α. These results are consistent with
increased expression of CCR3 (the RANTES receptor), which was only observed in TNF-α-
treated MSCs.
Several studies report expression of SDF-1α by MSCs. Liu and colleagues report that SDF-
1α protects MSCs from oxidative stress by activating the Akt and Erk survival pathways [46].
In addition, SDF-1α increased secretion of bFGF and VEGF by MSCs. In 2014, Gong and col-
leagues reported that the SDF-1/CXCR4 axis regulated migration of MSCs toward the pan-
creas in a rat model of acute pancreatitis [47]. In addition, studies of myocardial ischemia,
fracture, and cerebral ischemia report that bone marrow-derived MSCs migrate to sites of
inflammation in response to SDF-1α [21, 46, 48–56]. Thus, it is likely that MSC migration in
CAIA mice might be driven by RANTES and SDF-1α. Further studies should isolate spleno-
cytes isolated from CAIA mice treated with or without MSCs and treat them with/without
RANTES or SDF-1α. In addition, confirming RANTES and SDF-1α expression in tissues of
CAIA mice would be useful.
Here, we confirmed that MSCs migrate to the joints of mice with CAIA. Migrated MSCs
altered expression of FOXP3 and IL-17 in the mouse forepaw (Fig 2B and 2C). We expected
that FOXP3 levels would increase due to induction of immunoregulatory pathways; however,
we found that IL-17 levels increased as well. IL-17 levels were lower in control CAIA mice
than in wild-type DBA/1J mice or CAIA mice injected with MSCs. IL-17 plays a role in various
pathological processes, including inflammation and immune responses; however, studies sug-
gest that it plays a different role after MSC injection [57, 58]. Indeed, one study reports that IL-
17 plays a role in MSC migration and motility [59]. However, further studies are required if we
are to fully understand the role of IL-17 in CAIA mice and MSCs.
We also confirmed that expression of mFOXP3 was rather unique in the forepaw and
spleen (S1 Fig and Fig 2). Although there was no significant difference in FOXP3 mRNA
expression in the spleen of CAIA mice treated with or without MSCs, FOXP3 protein levels in
CAIA mice injected with MSCs were higher than in those not injected with MSCs. This result
is difficult to interpret/explain; however, we assume that it might be caused by a signal that
inhibits expression of FOXP3 in the mouse spleen. A previous study shows that FOXP3 is sup-
pressed by several growth factors or cytokines. Huber and colleagues showed that expression
of FOXP3 in cultured T cells (induced by TGFβ signaling) was suppressed by IL-27 [60].
Another study confirmed the presence of IL-27 in the spleen and joint tissues of a proteogly-
can-induced arthritis (PGIA) model [61]. In addition, another study found increased levels of
circulating IL-27 in patients with RA [62]. Therefore, IL-27 may be highly expressed in spleen
tissue of CAIA mice; however, no report has examined expression of IL-27 in these mice spe-
cifically. Thus, there are several theories that may explain our observations; however, it is clear
that further studies are required.
The present study focused on the migratory properties of MSCs and the interaction
between MSCs and T cells. To explain the therapeutic mechanism underlying the effects of
MSCs on CAIA, regulation of innate immunity by MSCs should be addressed. Previous
research indicates that MSCs modulate the behavior of macrophages and dendritic cells,
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thereby suppressing inflammation. Further studies are required to examine MSC-mediated
regulation of innate immune responses that do not involve T cell-mediated mechanisms.
The encouraging results of preclinical studies have led to clinical trials aimed at evaluating
the safety and efficacy of MSC-based therapy for autoimmune and inflammatory diseases [63].
Effective delivery of MSCs to sites of inflammation is mandatory for successful cell-mediated
therapy. Although the route of MSC administration is still a matter for debate, systemic
administration appears to be a feasible approach that results in suppression of local and sys-
temic inflammation. Intravenous infusion of expanded MSC populations into RA patients has
shown promising results, with a tolerable safety profile [64]. The homing properties of MSCs
would provide a wide range of opportunities to exploit cell-mediated therapy.
Taken together, the results presented herein suggest that MSCs are an effective treatment
for inflammatory arthritis because their migration to locally inflamed tissues contributes to
immune regulation. Although some issues need to be addressed prior to clinical application,
we believe that systemic administration of MSCs could be a feasible therapeutic option for RA
patients who are refractory to conventional treatment.
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S1 Fig. Expression of mouse FOXP3 and IL-17 in mouse spleen. There was no significant
difference between expression levels in wild-type, control CAIA, and MSC-treated CAIA
mice.
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S2 Fig. Image of the chemokine array panel. Expression of Axl, CD30T, CXCL16, SDF-1α,
and RANTES increased in the screening panel treated with peritoneal mononuclear cells from
CAIA mice treated with MSCs.
(JPG)
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